Logo
x

Search category

Subscribe Now

Roche

Roche Reports P-II Study (FENopta) Results of Fenebrutinib for the Treatment of Multiple Sclerosis

Roche Reports P-II Study (FENopta) Results of Fenebrutinib for the Treatment of Multiple Sclerosis

  • May 18, 2023
Roche Receives CHMP Recommendation for Approval of Columvi (glofitamab) to Treat Relapsed or Refractory Diffuse Large B-Cell Lymphoma in EU

Roche Receives CHMP Recommendation for Approval of Columvi (glofitamab) to Treat Relapsed or Refractory Diffuse Large B-Cell Lymph...

  • April 26, 2023
Top 20 Drugs with US Patent Expiry in 2023 Based on Total Sales Value

Top 20 Drugs with US Patent Expiry in 2023 Based on Total Sales Value

  • March 29, 2023
Roche’s Columvi (glofitamab) Receives Health Canada Authorization for the Treatment of Adult Patients with Diffuse Large B-cell Lymphoma

Roche’s Columvi (glofitamab) Receives Health Canada Authorization for the Treatment of Adult Patients with Diffuse Large B-cell Ly...

  • March 27, 2023
Insights+: EMA Marketing Authorization of New Drugs in February 2023

Insights+: EMA Marketing Authorization of New Drugs in February 2023

  • March 23, 2023
Nirja Patel, Senior International Product Manager at Roche Shares her Views on the US FDA Approval of the PATHWAY anti-HER2 Test

Nirja Patel, Senior International Product Manager at Roche Shares her Views on the US FDA Approval of the PATHWAY anti-HER2 Test

  • March 7, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.